Home > Search Results

Results: 3

Early and Locally Advanced Breast Cancer: Diagnosis and Treatment [Internet]

Early and Locally Advanced Breast Cancer: Diagnosis and Treatment [Internet]

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK)

Version: February 2009

Adjuvant systemic therapy

A proportion of patients with early invasive breast cancer will have occult metastatic disease at the time of diagnosis and will relapse at a later date. The purpose of adjuvant systemic treatment is to reduce this risk. Adjuvant therapy options include endocrine treatments, chemotherapy and targeted biological agents (such as trastuzumab, please see page 63); the selection of these is based on tumour and patient characteristics (see Chapter 4). Endocrine therapies include direct treatments such as tamoxifen and aromatase inhibitors and indirect treatments such as radiation menopause, medical oophorectomy by luteinising hormone-releasing hormone agonists (LHRHa) and ovarian ablation by surgery. Endocrine therapy with tamoxifen or an aromatase inhibitor should only be considered in patients with hormone receptor-positive tumours. The potential benefits of treatments have been assessed by the Early Breast Cancer Trialists Collaborative Group (EBCTCG), which is updated every 5 years.

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...